Nexvet Biopharma plc·4

Sep 7, 5:40 PM ET

Nexvet Biopharma plc 4

4 · Nexvet Biopharma plc · Filed Sep 7, 2016

Insider Transaction Report

Form 4
Period: 2016-09-05
HORN JURGEN
Chief Product Development Ofcr
Transactions
  • Exercise/Conversion

    Restricted Share Units

    2016-09-05+63,00063,000 total
    Exercise: $0.13Exp: 2021-07-01Ordinary Shares (63,000 underlying)
Footnotes (1)
  • [F1]15,750 of the Restricted Share Units shall vest and become convertible on each of 7/1/17, 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.

Documents

1 file
  • 4
    edgar.xmlPrimary

    PRIMARY DOCUMENT